Medical Technology In India Said To Lag Pharma By 20 Years
This article was originally published in PharmAsia News
Executive Summary
India's medical technology today is at a development point occupied by the nation's pharmaceutical industry 20 years ago, a manufacturer says. G.S.K. Velu, managing director of Trivitron Group, said the Indian government has been focusing on the drug industry to the detriment of the medical technology industry, accounting for the lag. His industry, he said, has enjoyed no large-scale initiative such as that provided the drug industry, leaving the market to multinational companies free to trade in India without an Indian presence. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.